Literature DB >> 26156535

Bone kidney interactions.

Thomas L Nickolas1, Sophie A Jamal.   

Abstract

The fact that bone disease and kidney disease co-exist is well known. Formally, this inter-relationship is called chronic kidney disease mineral bone disorder or CKD-MBD. Traditionally, it was thought that bone played a passive role in CKD-MBD - specifically that kidney disease caused disordered mineral metabolism which resulted in bone disease and ultimately fractures. More recently however our understanding of bone function in general and the role that bone plays in CKD-MBD in particular, has changed. This chapter will briefly review epidemiology of fractures in chronic kidney disease (CKD) and the roles that imaging and measuring markers of mineral metabolism can play in assessing fracture risk. We will then review more recent data consistent with the concept MBD occurs early in the course of CKD and, via the secretion of novel molecules and/or signalling pathways, the bone can influence other organ systems.

Entities:  

Mesh:

Year:  2015        PMID: 26156535     DOI: 10.1007/s11154-015-9314-3

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  54 in total

1.  Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.

Authors:  Johann Herberth; Adam J Branscum; Hanna Mawad; Tom Cantor; Marie-Claude Monier-Faugere; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2010-03-27       Impact factor: 8.860

2.  Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study.

Authors:  Ralf Koos; Vincent Brandenburg; Andreas Horst Mahnken; Rebekka Schneider; Guido Dohmen; Rüdiger Autschbach; Nikolaus Marx; Rafael Kramann
Journal:  J Heart Valve Dis       Date:  2013-05

3.  Relationship between moderate to severe kidney disease and hip fracture in the United States.

Authors:  Thomas L Nickolas; Donald J McMahon; Elizabeth Shane
Journal:  J Am Soc Nephrol       Date:  2006-09-27       Impact factor: 10.121

4.  LRP6 mutation in a family with early coronary disease and metabolic risk factors.

Authors:  Arya Mani; Jayaram Radhakrishnan; He Wang; Alaleh Mani; Mohammad-Ali Mani; Carol Nelson-Williams; Khary S Carew; Shrikant Mane; Hossein Najmabadi; Dan Wu; Richard P Lifton
Journal:  Science       Date:  2007-03-02       Impact factor: 47.728

5.  Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials.

Authors:  Ann V Schwartz; Anne L Schafer; Andrew Grey; Eric Vittinghoff; Lisa Palermo; Li-Yung L Lui; Robert B Wallace; Steven R Cummings; Dennis M Black; Douglas C Bauer; Ian R Reid
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

6.  The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease.

Authors:  Justine Bacchetta; Stéphanie Boutroy; Fitsum Guebre-Egziabher; Laurent Juillard; Jocelyne Drai; Solenne Pelletier; Michel Richard; Anne Charrié; Marie Christine Carlier; Roland Chapurlat; Maurice Laville; Denis Fouque
Journal:  Nephrol Dial Transplant       Date:  2009-06-10       Impact factor: 5.992

7.  Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin.

Authors:  C M Gundberg; S D Nieman; S Abrams; H Rosen
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

8.  Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.

Authors:  S Okuno; E Ishimura; N Tsuboniwa; K Norimine; K Yamakawa; T Yamakawa; S Shoji; K Mori; Y Nishizawa; M Inaba
Journal:  Osteoporos Int       Date:  2012-05-12       Impact factor: 4.507

9.  Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice.

Authors:  Ina Kramer; Gabriela G Loots; Anne Studer; Hansjoerg Keller; Michaela Kneissel
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

10.  Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients.

Authors:  Madhumathi Rao; Priyanka Jain; Temitope Ojo; Gautam Surya; Vaidyanathapuram Balakrishnan
Journal:  Int J Nephrol       Date:  2012-07-02
View more
  9 in total

Review 1.  X-linked hypophosphatemia and growth.

Authors:  R Fuente; H Gil-Peña; D Claramunt-Taberner; O Hernández; A Fernández-Iglesias; L Alonso-Durán; E Rodríguez-Rubio; F Santos
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 2.  Evaluation of fracture risk in chronic kidney disease.

Authors:  Pablo Antonio Ureña Torres; Martine Cohen-Solal
Journal:  J Nephrol       Date:  2017-04-06       Impact factor: 3.902

3.  High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice.

Authors:  Hai-Tao Hou; Ya-Nan Wang; Shi-Ze Shao; Song Fu; Xiang-Peng Huang; Xiao-Hui Wang
Journal:  Exp Ther Med       Date:  2018-02-14       Impact factor: 2.447

Review 4.  Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.

Authors:  Valeria Cernaro; Domenico Santoro; Antonio Lacquaniti; Giuseppe Costantino; Luca Visconti; Antoine Buemi; Michele Buemi
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-02-02

Review 5.  AMP-Activated Protein Kinase (AMPK)-Dependent Regulation of Renal Transport.

Authors:  Philipp Glosse; Michael Föller
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923

6.  Thyroid and bone turnover markers in type 2 diabetes: results from the METAL study.

Authors:  Yi Chen; Wen Zhang; Chi Chen; Yuying Wang; Ningjian Wang; Yingli Lu
Journal:  Endocr Connect       Date:  2022-03-31       Impact factor: 3.335

7.  Trabecular bone score and phalangeal quantitative ultrasound are associated with muscle strength and fracture risk in hemodialysis patients.

Authors:  Antonino Catalano; Agostino Gaudio; Federica Bellone; Mattia Miriam La Fauci; Anastasia Xourafa; Guido Gembillo; Giorgio Basile; Giuseppe Natale; Giovanni Squadrito; Francesco Corica; Nunziata Morabito; Domenico Santoro
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-07       Impact factor: 6.055

8.  FGF-2 suppresses expression of nephronectin via JNK and PI3K pathways.

Authors:  Tadashi Kato; Atsushi Yamada; Mikiko Ikehata; Yuko Yoshida; Kiyohito Sasa; Naoko Morimura; Akiko Sakashita; Takehiko Iijima; Daichi Chikazu; Hiroaki Ogata; Ryutaro Kamijo
Journal:  FEBS Open Bio       Date:  2018-04-19       Impact factor: 2.693

Review 9.  Bone Fragility Fractures in CKD Patients.

Authors:  Ana Pimentel; Pablo Ureña-Torres; Jordi Bover; Jose Luis Fernandez-Martín; Martine Cohen-Solal
Journal:  Calcif Tissue Int       Date:  2020-11-21       Impact factor: 4.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.